HUTCHMED Starts Global Trial of HMPL-A580 for Solid Tumours
HUTCHMED has initiated a global clinical trial of HMPL-A580, a PI3K/PIKK-EGFR ATTC candidate, in patients with solid tumours. The study marks the second clinical programme from its next-generation ATTC platform, targeting both PAM pathway and EGFR signaling to enhance therapeutic synergy.
Clinical Programme | 06/03/2026 | By News Bureau
Newron Pharmaceuticals Secures Euro 38 Million to Advance Phase III Schizophrenia Programme
Newron Pharmaceuticals strengthens its funding base with a multi-tranche equity raise to support late-stage development of evenamide in treatment-resistant schizophrenia.
Clinical Programme | 17/02/2026 | By News Bureau | 127
Alphyn Closes USD 25 Million Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Alphyn has closed an oversubscribed USD 25 million Series B financing round to support its dermatology pipeline, including a global Phase II (b) trial in atopic dermatitis and a Phase II clinical programme in molluscum contagiosum.
Clinical Programme | 16/12/2025 | By News Bureau | 283
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy